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Chronic myeloid leukaemia (CML) is caused by a defined genetic
abnormality that generatesBCR-ABL, a constitutively active tyrosine
kinase1. It is widely believed that BCR-ABL activates Akt signalling
that suppresses the forkhead O transcription factors (FOXO), sup-
porting the proliferation or inhibiting the apoptosis of CML cells2–4.
Although the use of the tyrosine kinase inhibitor imatinib is a break-
through for CML therapy, imatinib does not deplete the leukaemia-
initiating cells (LICs) that drive the recurrence of CML5–8. Here,
using a syngeneic transplantation system and a CML-like myelo-
proliferative disease mouse model, we show that Foxo3a has an
essential role in the maintenance of CML LICs. We find that cells
with nuclear localization of Foxo3a and decreased Akt phosphoryla-
tion are enriched in the LIC population. Serial transplantation of
LICs generated from Foxo3a1/1 and Foxo3a2/2mice shows that the
ability of LICs to cause disease is significantly decreased by Foxo3a
deficiency. Furthermore, we find that TGF-b is a critical regulator of
Akt activation in LICs and controls Foxo3a localization. A combina-
tion of TGF-b inhibition, Foxo3a deficiency and imatinib treatment
led to efficient depletion of CML in vivo. Furthermore, the treatment
of human CML LICs with a TGF-b inhibitor impaired their colony-
formingability in vitro.Our results demonstrate a critical role for the
TGF-b–FOXO pathway in the maintenance of LICs, and strengthen
our understanding of the mechanisms that specifically maintain
CML LICs in vivo.
Although tyrosine kinase inhibitor (TKI) therapy of CML patients
efficiently induces the death of leukaemia cells5–8, LICs in these
patients can survive this therapy. To understand the molecular
mechanisms maintaining CML LICs, we characterized LICs in vivo
using a mouse model for CML-like myeloproliferative disease
(MPD)9. Consistent with previous reports10–13, we found that a rare
c-Kit1Lineage2(Lin2)Sca-11 (KLS1) population of CML cells (that
is, bearing markers of normal haematopoietic stem cells (HSCs))
induced efficient CML development in recipient mice (Supplemen-
tary Fig. 1). In contrast, neither c-Kit1Lin2Sca-12 (KLS2) cells
(which correspond to normal progenitors), nor other CML cell
populations expressing differentiation markers, induced CML.
Weandothers have shown that Foxo transcription factors,which are
important downstream targets of PI3K-Akt signalling, are essential for
the maintenance of self-renewal capacity in normal HSCs14–16. When a
growth factor binds to the appropriate receptor, Akt is activated and
phosphorylates Foxo proteins, resulting in their nuclear export and
subsequent degradation in the cytoplasm. In the absence of growth
factor stimulation, Foxo proteins are retained in an active state in the
nucleus and induce their transcriptional targets. InCMLcell lines, BCR-
ABL is thought to activate PI3K-Akt signalling that leads to nuclear
export of Foxo factors and suppression of their transcriptional
activity2–4. However, we found that, whereas most KLS2 cells (non-
LICs) showed the expected cytoplasmic localization of Foxo3a, KLS1
cells (LICs) enriched cells with nuclear localization of Foxo3a (Fig. 1a
and Supplementary Fig. 2), as observed in normal HSCs15,17 (Sup-
plementary Fig. 3). LICs with nuclear Foxo3a also exhibited decreased
levels of phosphorylated Akt (p-Akt) compared to most non-LICs,
suggesting that Foxo3a remains active inLICsowing toAkt suppression.
We next examined the role of Foxo3a in CML initiation by establish-
ing Foxo3a-deficient CMLmodel. We isolated immature bone marrow
cells from Foxo3a1/1 and Foxo3a2/2 littermates15, infected these cells
with retrovirus carrying theBCR-ABL gene, and transplanted them into
syngeneic recipients (first bone marrow transplantation (BMT)). Both
recipient groups showed the same symptoms of CML-like MPD,
including increasedmyeloid cells inperipheral bloodand splenomegaly9
(Fig. 1b, c, left and Supplementary Figs 4 and 5). Thus, Foxo3a was
dispensable for the generation of CML-like disease. After a first BMT,
the absolute numbers of Foxo3a2/2 LICs in recipient spleen and
bone marrow were significantly higher than the absolute numbers of
Foxo3a1/1 LICs present in recipient organs (Fig. 1d, left and Sup-
plementary Fig. 6a), although the in vitro colony-forming ability of these
Foxo3a1/1 and Foxo3a2/2 LICs was comparable (Fig. 1e, left).
When we transplanted Foxo3a1/1 and Foxo3a2/2 LICs from first
BMT mice into a new set of recipients (second BMT), there was no
difference in CML development (Fig. 1b, c, centre and Supplemen-
tary Figs 4 and 5). However, the in vitro colony-forming ability of
second BMTLICs was decreased by loss of Foxo3a (Fig. 1e, right). In a
third BMT, relatively mild CML-like MPD developed in recipients
within one month. Foxo3a deficiency prevented the propagation of
CML cells in the peripheral blood and spleen in vivo (Fig. 1b, right and
Supplementary Figs 4 and 5). Furthermore, the absolute numbers of
Foxo3a2/2 LICs in the organs of third BMT recipients were much
lower than in third BMT recipients that had received Foxo3a1/1
LICs (Fig. 1d, right and Supplementary Fig. 6). Thus, Foxo3a2/2
LICs may retain sufficient function to cause disease in second BMT
recipients but succumb to exhaustion in third BMT recipients.
Although CML-like MPD developed in mice that had received either
Foxo3a1/1 or Foxo3a2/2 LICs within 40 days of a third BMT (Sup-
plementary Fig. 5a, b), recipients of Foxo3a1/1 LICs also developed
acute lymphocytic leukaemia (ALL), as well as CML, 40 days after the
third BMT (Supplementary Fig. 5c) as reported18, suggesting that these
LICs can generatemalignancies in several lineages. Notably, we did not
observe development of ALL or CML in recipients of Foxo3a2/2 LICs
45 days after a third BMT (Supplementary Fig. 5c), suggesting that the
Foxo3a2/2 LICs lose their potential to generate malignancies. This
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inability of Foxo3a2/2 LICs to induce or sustain leukaemia resulted in
the reduced lethality of these animals (Fig. 1c, right). Thus, Foxo3a is
essential for the long-termmaintenance of leukaemia-initiating poten-
tial. Because the introduction of a dominant-negative Foxomoiety into
CML LICs impaired LIC function in vivo (Supplementary Fig. 7), the
defective maintenance of Foxo3a2/2 LICs is probably due to a dimi-
nution in LIC self-renewal activity rather than a defect in the original
HSCs. Furthermore, the Foxo4 protein expression pattern in LICs is
very similar to that of Foxo3a (Supplementary Fig. 8), suggesting an
overlap in Foxo functions.
We next determined how Foxo3a deficiency impaired the main-
tenance of the CML-initiating potential of LICs. Loss of Foxo3a did
not affect LIC differentiation potential (Fig. 2a) or cell cycle status
(Fig. 2b), although LICs with nuclear localization of Foxo3a showed
lower expression of the Ki67 antigen (Supplementary Fig. 9).
However, TdT-mediated dUTP nick end labelling (TUNEL)-positive
apoptotic cells were significantly increased in histological sections of
bone marrow and spleen from Foxo3a2/2 CML-affected mice
compared to controls (Fig. 2c, d). To confirm that this apoptosis was
occurring in LICs, we purified KLS1 cells and showed that the fre-
quency of Annexin-V1 or TUNEL1 cells among Foxo3a2/2 KLS1
cells was higher than among Foxo3a1/1 KLS1 cells (Fig. 2e, f). Thus,
Foxo3a is required for LIC survival because it mediates suppression
of apoptosis.
An intriguing question in current CML research is how Akt is
inactivated (and thus Foxo is activated) mainly in LICs, despite
BCR-ABL expression in all CML cells. The fact that TGF-b regulates
Akt activation (and thus nuclear Foxo3a) in normal HSCs prompted
us to assess whether TGF-b signalling controls Foxo localization in
CML LICs19. We first examined the phosphorylation of Smad2/3
proteins, which are downstream effectors in the TGF-b signalling
pathway20. Phosphorylation of Smad2/3 in the nuclei of CML
KLS1 cells was higher than that in KLS2 cells (Fig. 3a and Sup-
plementary Fig. 10), indicating that TGF-b signalling was activated
in CML LICs. We then treated CML KLS1 cells in vitro for 2 h with
either TGF-b1 or theTGF-b inhibitor Ly364947 (ref. 21) and analysed
Foxo3a localization. TGF-b1 treatment increased Foxo3a nuclear
localization, whereas Ly364947 promoted nuclear export of Foxo3a
(Fig. 3b–d and Supplementary Fig. 11). Furthermore, KLS1 cells
treated with TGF-b1 showed high Smad2/3 and low Akt phosphor-
ylation levels, whereas cells treated with Ly364947 exhibited the
opposite pattern (Fig. 3b, c and Supplementary Figs 11 and 12). The
activity of mTOR complex 1 (mTORC1), which was determined by
assessing the phosphorylation of S6 ribosomal protein22, correlated
positively with p-Akt levels in these KLS1 cells (Fig. 3d and Sup-
plementary Fig. 13). We propose that TGF-b signalling controls Akt
activity in LICs, leading to retention of Foxo3a in the nucleus.
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Figure 1 | Maintenance of CML LICs depends on Foxo3a. a, Decreased Akt
phosphorylation and increased Foxo3a nuclear localization in CML LICs.
BCR-ABL-GFP1 KLS2 and KLS1 cells were immunostained to detect p-Akt
and Foxo3a. Nuclei were visualized using 49,6-diamidino-2-phenylindole
(DAPI; blue). Scale bars, 10 mm. b, Numbers of white blood cells (WBC) in
peripheral blood (PB) in Foxo3a1/1 (open circles) and Foxo3a2/2 (closed
squares) CML-affected mice at first to third BMT. Data shown are the mean
WBC number6 s.d. (n5 4). c, d, Survival rate (c) and absolute number of
LICs (d) in CML-affected mice. Data are expressed as percentage survival
(c) and absolute number of LICs6 s.d. in spleen (d). e, In vitro colony-
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Figure 2 | Essential role of Foxo3a in suppression of LIC apoptosis.
a,b, Comparable differentiationpotential and cell cycle status in vivo. a, Data
show the mean percentage6 s.d. of CMP (common myeloid progenitors)-,
GMP (granulocyte-macrophage progenitors)-, and MEP (megakaryocyte-
erythroid progenitors)-like cells in BCR-ABL-GFP1 bone marrow cells
(n5 3). b, Data are the mean frequency of BrdU1 cells6 s.d. (n5 3).
c–f, Increased apoptosis of Foxo3a2/2 LICs. c, d, Histological sections of
bone marrow (c) and spleen (d) from Foxo3a1/1 or Foxo3a2/2 CML-
affected mice at second BMT were analysed by TUNEL staining (red) and
DAPI. Scale bars, 100mm. e, Mean percentage6 s.d. of Annexin-V1 cells
among GFP1KLS1 cells (n5 3). f, LICs were subjected to TUNEL staining.
Scale bars, 50 mm.
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Notably, as TGF-b did not efficiently induce nuclear localization of
Foxo3a in non-LICs (KLS2) cells (Supplementary Figs 14–16), there
seem to be differences in how TGF-b-stimulated Foxo3a activation is
regulated in LICs and non-LICs.
These findings led us to evaluate the effects of inhibition of TGF-b–
Foxo signalling on the CML-initiating potential of LICs.
Interestingly, TGF-b inhibitors (Ly364947, SD208) suppressed LIC
colony-forming ability after co-culture with OP-9 stromal cells,
which are used to maintain normal HSCs ex vivo and mimic their
in vivo environment23 (Fig. 3e and Supplementary Fig. 17a).
Furthermore, although imatinib treatment alone of LICs co-cultured
with OP-9 cells reduced the colony-forming capacity of Foxo3a1/1
CML LICs, the addition of TGF-b inhibitor significantly enhanced
the inhibitory effect of imatinib onLIC colony-forming ability (Fig. 3f
and Supplementary Figs 17b, c and 18a), consistent with a report in
which TGF-b inhibition enhanced imatinib-induced cell death24.
Although Foxo3a deficiency alone did not affect LIC colony-forming
ability (Fig. 1e, left), significantly fewer colonies arose from
Foxo3a2/2 LICs treated with imatinib compared to treated
Foxo3a1/1 LICs (Fig. 3f). When imatinib was combined with
Foxo3a deficiency and Ly364947, there was no further inhibitory
effect compared to either Foxo3a deficiency or Ly364947 treatment
alone (Fig. 3f). TGF-b inhibition had no effect on the colony-forming
ability of normal KLS1 cells under the same experimental conditions
(Supplementary Fig. 18b). These data indicate that Foxo3a is an
important downstream effector in the TGF-b signalling pathway
driving the survival of LICs exposed to TKI therapy, and that inhibi-
tion of Foxo or TGF-bmay be a highly useful adjunct to TKI therapy.
To test this hypothesis in vivo, we administered imatinib to second
BMT mice bearing Foxo31/1 or Foxo3a2/2 CML LICs. Without
imatinib, 80% of both groups died within 60 days (Fig. 4a). Admini-
stration of imatinib alone delayed CML onset and reduced recipient
lethality, but 60% of the treated mice that had received Foxo3a1/1
LICs diedwithin 90 days. In contrast, imatinib combinedwith Foxo3a
deficiency significantly increased the survival of CML-affected mice.
Moreover,whenwe isolated the residualKLS1populations from these
imatinib-treated recipients, we found that Foxo3a deficiency had
reduced both the number and colony-forming ability of these LICs
(Supplementary Fig. 19). Thus, Foxo3a is essential for the ability of
CML LICs to survive imatinib therapy.
We then investigated the in vivo effect of a TGF-b inhibitor on LIC
functions. Administration of Ly364947 alone led to increased p-Akt
levels and decreased nuclear Foxo3a in LICs (Fig. 4b and
Supplementary Fig. 20), demonstrating that TGF-b is a critical regu-
lator of Akt and Foxo in LICs in vivo. Unlike the suppressive effect
exerted by TGF-b in vitro, administration of Ly364947 alone did not
extend the survival of second BMT Foxo3a1/1mice with overt CML.
However, Ly364947 combined with imatinib significantly reduced
recipient lethality, decreased CML infiltration in lung (Fig. 4c and
Supplementary Fig. 21a), and decreased LIC frequency (Supplemen-
tary Fig. 21b, c). These in vivo data suggest that CML LICs are more
sensitive than normal HSCs/progenitors to TGF-b inhibitors.
Finally, we further confirmed that the suppressive effects of TGF-b
inhibitors on mouse CML LIC function are also observed in human
CML LICs. We isolated CD341CD382Lin2 cells as human CML
LICs12 from bone marrow cells of human CML patients, and co-
cultured them on OP-9 cells with or without Ly364947. Ly364947
reduced the number of colonies formed by human CML LICs
(Fig. 4d) and enhanced the inhibitory effects of imatinib on human
CML LICs (Fig. 4e), suggesting that TGF-b–FOXO signalling also
governs the behaviour of human CML LICs.
Our study indicates a model in which Foxo3a has opposite effects
on the survival of LICs and non-LICs (Fig. 4f and Supplementary
Discussion 1). In non-LICs, BCR-ABL drives strong Akt activation
that forcefully represses Foxo3a functions. When TKIs block BCR-
ABL and reduce Akt activation, activation of Foxo3a leads to apop-
tosis or cell cycle arrest. In contrast, in LICs, Akt activity is suppressed
despite BCR-ABL expression in vivo, leading to nuclear localization
of Foxo3a. Although a previous study suggested that Foxo3a may
contribute to the acquisition of dormancy in leukaemia cells after
exposure to anti-leukaemic agents2, our data demonstrate that LICs
have properties that allow them to resist various stress in vivo in a
Foxo-dependent manner. Notably, we found that the role of Foxo3a
in a CML blast crisis model was different from that in this MPD
model (Supplementary Figs 22 and 23), indicating that Foxo proteins
can mediate different regulatory mechanisms in different phases and
types of leukaemia.
It remains unclear precisely how Akt and Foxo signalling is con-
trolled in LICs in vivo. The presence of TGF-b1 in CML LICs
(Supplementary Fig. 24) and the in vitro effects of TGF-b inhibitor
on Foxo3a localization in LICs suggest that a cell-autonomous effect
of TGF-b may control Foxo3a function in vivo. However, when we
cultured LICs with TGF-b inhibitors in a stroma-free system, colony
formation was not inhibited (Supplementary Fig. 25), suggesting that
the survival and/or proliferation of LICs depends not only on TGF-b
produced by LICs themselves but also on TGF-b in the surrounding
microenvironment. Alternatively, TGF-b signalling in niche in vivo
may affect LIC behaviour in a manner mediated by unknown factors.
In any case, it appears that LICs are controlled by a complicated
network of TGF-b signalling.
Although our study suggests that inhibition of the TGF-b–FOXO
axismight represent a new therapeutic approach for CMLpatients, the
application of TGF-b or FOXO inhibitors to the treatment of haema-
tological malignancies warrants careful consideration (Supplementary
Discussion 2). Our future workwill be focused on further understand-
ing how the LICs are maintained in vivo.
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Figure 3 | TGF-b–Foxo signalling is required for the colony-forming
capacity of LICs. a, Increased Smad2/3 phosphorylation in LICs. Foxo3a1/1
KLS1 and KLS2 CML cells were immunostained to detect Foxo3a and
phosphorylated-Smad2/3 (p-Smad2/3). b–d, Control of Foxo3a localization
by TGF-b signalling. LICs were treated in vitrowith TGF-b1 or Ly364947 for
2 h followed by immunostaining to detect Foxo3a and (b) p-Smad2/3,
(c) p-Akt or (d) phosphorylated-S6 (p-S6). Scale bars, 10 mm. e, Inhibition of
TGF-b decreases LIC colony-forming ability. Representative data shown are
the mean LIC colony number6 s.d. (n5 3). f, TGF-b inhibition or Foxo3a
deficiency enhances imatinib-mediated inhibition of LIC colony-forming





For our mouse CML model, normal immature bone marrow cells (KLS1) from
C57BL/6 mice were infected with retrovirus carrying MSCV-BCR-ABL-ires-
GFP10,12,13. The transducedKLS1 cellswere transplanted intravenously into lethally
irradiated (9.5Gy) C57BL/6 congenic mice along with 53 105 bone marrow
mononuclear cells from C57BL/6 mice. The development of CML-like MPD
was confirmed by morphological analysis and marker determinations. To analyse
phenotypes of LICs, the GFP1KLS1 subpopulation frombonemarrow and spleen
was purified and transplanted into syngeneic recipients along with 53 105 bone
marrowmononuclear cells. To examine Foxo3a in themaintenance of CML LICs,
Foxo3a2/2 and Foxo3a1/1 littermates (C57BL/6; F4) were subjected to the above
protocol. For Akt activity, TGF-b signalling and Foxo3a localization, freshly iso-
lated GFP1KLS1 andKLS2 subpopulations, or GFP1KLS1 cells incubated for 2 h
with 5 ngml21 TGF-b1 (R&DSystems) or 10mMLy364947 (Merck), were immu-
nostained with anti-p-Akt (Cell Signaling), anti-phospho-S6 (Cell Signaling),
anti-phospho-Smad2/3 (Millipore), or anti-Foxo3a (Sigma). To examine
colony-forming ability in vitro, GFP1KLS1 cells were cultured in semi-solid
methylcellulose medium (stroma-free)15, or were co-cultured for 5 days on OP-9
stromal cells with Ly364947 (10mM). For experiments involving imatinib,
GFP1KLS1 cells were cultured onOP-9 cells with or without 5mMimatinib (kind
gift from Novartis), followed by washing and transfer to semi-solid medium.
Human LICs were purified as CD341CD382Lin2 cells of bonemarrow cells from
CML patients (Cureline, Inc. and AllCells). These cells were co-cultured on OP-9
cells for 5 days before transfer to semi-solidmedium.Cell cyclingwas assessedby in
vivo BrdU incorporation (12 h). Apoptosis was assayed by TUNEL (Roche) or
Annexin-V (Abcam) staining. Recipient mice bearing Foxo3a1/1 or Foxo3a2/2
CML LICs received either imatinib by oral gavage twice a day for 80days at
200mgkg21 (of bodyweight) per day, or Ly364947 by intraperitoneal administra-
tion for 80days at 10 mgkg21 (of body weight) every 2 days.
Note added in proof: During the reviewing process, a paper demonstrating that
human CML stem cells show predominant nuclear localization of FOXO
proteins was published25. The study supports our conclusion about the import-
ant roles of FOXO in CML LICs.
Full Methods and any associated references are available in the online version of
the paper at www.nature.com/nature.
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Figure 4 | Inhibition of TGF-b–Foxo3a signalling in combination with TKI
therapy depletes CML in vivo. a, Foxo3a deficiency promotes the survival of
imatinib-treated CML mice in a second BMT. At 10 days after BMT, mice
transplanted with Foxo3a1/1 or Foxo3a2/2 LICs (1.53 104) received either
vehicle (control) or imatinib for 80 days, and the percentage survival was
determined. b, Ly364947 administration to CML-affected mice (25mg kg21
for 7 days) increases p-Akt and decreases nuclear Foxo3a in LICs. Scale bars,
10 mm. c, Combined administration of Ly364947 and imatinib prolongs the
survival of CML-affected mice. At 10 days after BMT, recipients received
dimethyl sulphoxide (DMSO) or Ly364947 plus vehicle (control) or
imatinib for 80 days, and the percentage survival was determined.
d, e, Inhibition of TGF-b decreases the in vitro colony-forming ability of
human CML LICs. CD341CD382Lin2 cells from bone marrow of CML
patients were co-cultured on OP-9 cells with either DMSO (2) or Ly364947
(1) for 5 days in the absence (d) or presence (e) of imatinib. Data shown are
the mean colony number6 s.d. (n5 3). f, Scheme outlining the proposed
distinct roles of Foxo3a in non-LICs versus CML LICs.
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Mice. Foxo3a2/2 and littermate Foxo3a1/1 mice of the C57BL/6 (F4) genetic
background15 were used in this study. C57BL/6 congenic mice were purchased
from Sankyo-Lab Service. Animal care in our laboratory was in accordance with
the guidelines for animal and recombinant DNA experiments of Kanazawa
University. Imatinib (Glivec; purchased from Novartis) was administered to
mice by oral gavage twice a day (200mg kg21 of body weight per day in water).
Ly364947 (Merck Chemicals Ltd) was prepared as a 5mgml21 stock solution in
DMSO and intraperitoneally administered in saline to mice for 80 days at
10mg kg21 (of body weight) every 2 days, or for 7 days at 25mg kg21 (body
weight) per day.
Flow cytometry and cell sorting.A FACSaria (BDBiosciences) andmonoclonal
antibodies recognizing the followingmarkers were used for flow cytometry: Sca-1
(E13-161.7), CD4 (L3T4), CD8 (53-6.7), B220 (RA3-6B2), TER119 (Ly-76), Gr-1
(RB6-8C5), Mac1 (M1/70), IL7Ra chain (B12-1), FccIII/II receptor (2.4G2) and
CD34 (RAM34, pacific blue-conjugated) (all from BD Biosciences). Anti-c-Kit
(ACK2) monoclonal antibody was from eBiosciences. A mixture of monoclonal
antibodies recognizing CD4, CD8, B220, TER119, Mac1 and Gr-1 was used to
identify Lin1 cells.
Preparation of retrovirus. The cDNA encoding human BCR-ABL (gift fromH.
Honda) was cloned into the EcoRI site of the MSCV or MSCV-ires-GFP vector.
Retroviral packaging cells (Plat-E) were transiently transfected with the MSCV-
BCR-ABL-ires-GFP plasmid using FuGene6 reagent (Roche) and used for trans-
plantation into mice as described later.
Generation of CMLmodel and isolation of LIC population.Normal immature
c-Kit1Lin2Sca-11 haematopoietic cells (KLS1 cells) from Foxo3a2/2 and litter-
mate Foxo3a1/1 mice were purified by flow cytometry and cultured in serum-
free S-Clone SF-03 medium (Sanko Junyaku) supplemented with 10 ngml21
human TPO (thrombopoietin; PeproTech) plus 10 ngml21 mouse SCF (stem
cell factor; Wako Pure Chemical). To generate our CML-like MPD mouse
model, normal KLS1 cells were infected with the above retrovirus carrying
MSCV-BCR-ABL-ires-GFP using CombiMag (OZ Bioscience). The transduced
KLS1 cells were transplanted intravenously into lethally irradiated (9.5Gy)
C57BL/6 congenic mice along with 53 105 bone marrow mononuclear cells
from C57BL/6 mice.
For the prospective isolation of LICs, mononuclear cells were isolated from
bone marrow or spleen of CML-affected recipient mice at 12–14 days post-
transplantation, and GFP1 subpopulations (33 104) were recovered by flow
cytometric cell sorting, followed by transplantation into C57BL/6 congenic mice
as described earlier. For serial transplantations, GFP1 KLS1 cells (33 104 or
1.53 104) were collected and pooled from five BMTmice and transplanted into
a second set of lethally irradiated congenic recipient mice along with 53 105
normal bone marrow mononuclear cells from C57BL/6 mice. The absolute
number of CML LICs in the spleen of a recipient mouse was calculated as (total
number ofmononuclear cells isolated from the bonemarrow (two legs) or spleen
3 frequency of GFP1 KLS1 cells (%) 3 1/100).
Mouse cell colony-forming assay. Mouse cells were cultured in semi-solid
medium (stroma-free) containing the cytokines SCF, IL-3, IL-6 and erythro-
poietin15 (Methocult GFM3434; Stem Cell Technologies) at 37 uC in humidified
air containing 5% CO2 for 7 days. For co-culture assays, cells (13 10
3) were co-
cultured on OP-9 stromal cells23 under hypoxic conditions (5% O2) for 5 days.
After collecting and washing with PBS, colony formation was assessed in semi-
solid medium as described earlier. For inhibition of TGF-b signalling, cells were
co-cultured on OP-9 stromal cells in the presence of control (DMSO) or 2, 10 or
20 mM Ly364947 or SD208 (Sigma) for 5 days, followed by washing and transfer
to semi-solid medium. For the combination treatment of TGF-b inhibitor plus
imatinib, cells were first treated with DMSO or a TGF-b inhibitor on OP-9
stromal cells. At 24 h after starting culture, the cells were treated with further
DMSO or 5 mM imatinib (STI571; provided by Novartis) and incubated for
another 4 days (total 5 days). Thereafter, the cells were washed with PBS and
transferred to semi-solid medium. The number of colonies was counted under
the microscope.
Fluorescence immunostaining. Freshly isolated cells were incubated in S-Clone
medium without cytokines for 30min on poly-L-lysine (Sigma)-coated glass
slides26 at 37 uC under hypoxic conditions (5% O2). To examine the effects of
TGF-b signalling, cells were treated with 5 ngml21 TGF-b1 (R&D Systems), 10
mMLy364947 (Merck), or vehicle control at 37 uC for 2 h. After fixation with 4%
paraformaldehyde for 30min and permeabilization with 0.25%Triton X-100 for
2min, the cells were blocked by incubation in 2%BSA/PBS for 1 h. For immuno-
staining, the permeabilized cells were incubated with mouse or rabbit anti-
FKHRL1 (Foxo3a) (FR1 or F2178; Sigma), rabbit anti-Foxo4 (9472; Cell
Signaling), rabbit anti-phospho-Smad2/3 (Millipore), rabbit anti-phospho-
Akt (D9E; Cell Signaling), or rabbit anti-phospho-S6 ribosomal protein (2211;
Cell Signaling) antibodies at 4 uC for 12 h. Primary antibodies were visualized by
incubating the cells with AlexaFluor 546- or AlexaFluor 647-conjugated goat
anti-mouse IgG or goat anti-rabbit IgG (Molecular Probes). Nuclei were stained
with the DNA marker DAPI (Sigma). Stained slides were mounted using
Fluoromount Plus (Diagnostic Biosystems), and fluorescent images were
acquired using a Fluoview 1000 laser confocal microscope (Olympus) and
Photoshop software (Adobe). Fluorescence intensities were quantified using
ImageJ software. To evaluate the subcellular localization of Foxo3a, approxi-
mately 100 cells per group were counted under the microscope.
Cell cycle analysis and differentiation potential. To determine the cell cycle
status of LICs in vivo, second BMT CML mice were administered BrdU intra-
peritoneally (100mg kg21 of body weight in saline; Sigma) for 12 h. Numbers of
BrdU1 LICs were assessed by immunostaining with anti-BrdU antibody (3D4;
BD Biosciences) and flow cytometry. To examine the cell cycle status of LICs in
vivo and determine the nuclear localization of Foxo3a, cells were co-stained with
rabbit anti-FKHRL1 antibody (F2178; Sigma) to detect Foxo3a, and anti-mouse
Ki67 antibody (B56; BD Biosciences).
To evaluate differentiation potential, the frequencies of CMP-like
(CD341FccIII/II receptor2), GMP-like (CD341FccIII/II receptor1), and
MEP-like (CD342FccIII/II receptor2) cells among GFP1 bone marrow cells
obtained from Foxo3a1/1 and Foxo3a2/2 CMLmice at first BMT were analysed
by flow cytometry.
Detection of apoptosis. To determine apoptosis in vivo, freshly isolated spleens
and bones were immediately fixed with 4% paraformaldehyde, and tissue
sections were prepared and stained using the TUNEL method (Roche).
Isolated GFP1KLS1 cells from mice that had been transplanted with
Foxo3a1/1 and Foxo3a2/2CML LICs (second BMT) were either co-stained with
Annexin-V-PECy5 (Abcam) and examined by flow cytometry, or stained in vitro
using the TUNEL method (Roche).
Inhibition of endogenous Foxo by dominant-negative Foxo. Retroviruses
carrying a dominant negative (dn)Foxo vector (MSCV-dnFoxo-ires-GFP27) or
a control GFP vector (MSCV-ires-GFP) were generated as described earlier. To
obtain dnFoxo CML LICs, normal KLS1 cells (wild-type C57BL/6 CD45.1) were
infected with retrovirus carrying the BCR-ABL gene (without GFP). These
infected KLS1 cells were transplanted into irradiated recipient mice (C57BL/6
CD45.2). At 14 days after transplantation, donor-derivedKLS1 cellswere isolated
and infectedwith retrovirus carrying the control GFPor dnFoxo-ires-GFP vector.
To examine the reconstitutionofCMLLICs in vivo, retrovirus-infectedCMLLICs
(unfractionated) were transplanted intravenously into lethally irradiated C57BL/
6 congenicmice alongwith 53 105 bonemarrowmononuclear cells fromC57BL/
6 mice. At 14 days after transplantation, absolute numbers of GFP1KLS1 cells
were measured in recipient spleens. To examine LIC colony-forming ability in
vitro, these GFP1 CML LICs were cultured in semi-solid medium (stroma-free),
or were co-cultured on OP-9 stromal cells as described earlier.
Quantitative real-time RT–PCR analysis. RNA samples were purified from
fractionated GFP1KLS1 and GFP1KLS2 cells (1.03 105) using the RNeasy kit
(QIAGEN) and reverse-transcribed using the Advantage RT-for-PCR kit
(Takara-Clontech). Real-timequantitative PCRwas performedusing SYBR green
Premix EXTaq (Takara) on anMx3000PReal-time PCR system (Stratagene). The
following primers were used: Tgfb1, 59-TATGCTAAAGAGGTCACCCGCG-39
and 59-TGCTTCCCGAATGTCTGACG-39; Alk5 (also known as Tgfbr1), 59-GA
TCGCCCTTTCATTTCAGAGG-39 and 59-AAACCGACCTTTGCCAATGC-39;
Tgfbr2, 59-GAGAGCATGAAAGACAGTGTGC-39 and 59-CCAGCACTCGGTC
AAAGTCT-39; Actb, 59-AGGTCATCACTATTGGCAACGA-39 and 59-CACTT
CATGATGGAATTGAATGTAGTT-39. The following cycle parameters were
used: denaturation at 95 uC for 10 s, and annealing and elongation at 57 uC for
Actb, and 60 uC for Tgfb1, Tgfbr1 and Tgfbr2.
Analyses of primary human CML samples. Viable bone marrow mononuclear
cells from patients with chronic phase CML were purchased from Cureline, Inc.
(no. 16-122;) and AllCells LLC (no. 06-255 and 06-620). Cells were stained with
anti-CD34 (8G12), anti-CD38 (HIT2), anti-CD3 (SK7), anti-CD16 (3G8), anti-
CD19 (SJ25C1), anti-CD20 (L27), anti-CD14 (MwP9), and anti-CD56
(NCAM16.2) antibodies (all from BD Biosciences). A mixture of monoclonal
antibodies recognizing CD3, CD16, CD19, CD20, CD14 and CD56 was used to
identify Lin2 cells. CD341CD382Lin2 cells were purified by cell sorting. To
examine the effects of treatment with Ly364947 alone or a combination of
Ly364947 plus imatinib, CD341CD382Lin2 cells were cultured on OP-9
stromal cells as described earlier. After collecting and washing in PBS, the col-
ony-forming ability of LICs was evaluated by culture in semi-solid medium
containing SCF, GM-CSF, IL-3, IL-6, G-CSF and erythropoietin (Methocult
GF1 H4435; Stem Cell Technologies).
Generation of CML blast crisis model. A mouse model of CML blast crisis was
generated as previously described28. In brief, normal KLS1 cells were co-infected
with a retrovirus carrying MSCV-BCR-ABL-ires-GFP and a retrovirus carrying
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MSCV-NUP98/HOXA9. The transduced Lin2Sca-11 (LS1) cells11 were trans-
planted intravenously into lethally irradiated C57BL/6 congenic mice along with
53 105 bone marrow mononuclear cells from C57BL/6 mice.
Statistical analyses. Statistical differences were determined using the unpaired
Student’s t-test for P-values, and the long-rank non-parametric test for survival
curves.
26. Ema, H. et al. Adult mouse hematopoietic stem cells: purification and single-cell
assays. Nature Protocols 1, 2979–2987 (2006).
27. Bouchard, C. et al. FoxO transcription factors suppress Myc-driven
lymphomagenesis via direct activation of Arf. Genes Dev. 21, 2775–2787 (2007).
28. Dash, A. B. et al. A murine model of CML blast crisis induced by cooperation
between BCR/ABL andNUP98/HOXA9. Proc. Natl Acad. Sci. USA 99, 7622–7627
(2002).
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